AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06715839
Drug: [18F]F-RESCA-T4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[18F\]F-RESCA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
Trial: NCT06715839
Drug: [68Ga]Ga-NOTA-G5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[68Ga\]Ga-NOTA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-G5 injection.
Trial: NCT06715839
Drug: [18F]F-RESCA-G5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[18F\]F-RESCA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-G5 injection.
Trial: NCT06715839
Drug: [68Ga]Ga-NOTA-WWH347
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[68Ga\]Ga-NOTA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-WWH347 injection.
Trial: NCT06715839
Drug: [18F]F-RESCA-WWH347
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi/kg of a GPA33-targeted probe (\[18F\]F-RESCA-WWH347). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-WWH347 injection.
Trial: NCT06715839
Drug: [68Ga]Ga-NOTA-RND20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[68Ga\]Ga-NOTA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RND20 injection.
Trial: NCT06715839
Drug: [18F]F-RESCA-RND20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will receive 0.05-0.1 mCi/kg of a Nectin-4-targeted probe (\[18F\]F-RESCA-RND20). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RND20 injection.
Trial: NCT06457477
Drug: NAs
RxNorm normalized name: DNase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT05833035
Drug: BI 1291583 mixed with [C-14] BI 1291583
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1291583 mixed with \[C-14\] BI 1291583
Trial: NCT05745610
Drug: Shen Hai Long Capsule
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times/day (9 capsules/day) for 12 weeks
Trial: NCT05219253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) administered intramuscularly, one each at Day 1 and Month 2.
Trial: NCT06243614
Drug: Buagafuran capsules, 15mg/ capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants took 60-120 mg Buagafuran capsules daily. The initial dose was 60mg/ day, 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
Trial: NCT06243614
Drug: Buspirone tablets, 5mg/ tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants took 10-20mg Buspirone tablets daily. The initial dose was 10mg/ day, 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
Trial: NCT06243614
Drug: Buagafuran capsules mimic, 0mg/ capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants took Buagafuran capsules mimic daily. 2 to 4 capsules per time, twice per day, respectively, after breakfast and dinner for 8 weeks;
Trial: NCT06243614
Drug: Buspirone tablets mimic, 0mg/ tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants took Buspirone tablets mimic daily. 1 to 4 tablets per time, twice per day, respectively, after breakfast and dinner for 8 weeks.
Trial: NCT03712826
Drug: Anti-TNF Drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crohn patient with antiTNF treatment
Trial: NCT05759208
Drug: OK-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Solution
Trial: NCT05759208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00005010
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04726345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet to be taken orally once a day until stent removal.
Trial: NCT06332508
Drug: Anthracycline-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Anthracycline-based chemotherapy (doxorubicin, cyclophosphamide)~At dose levels 3 and 4, two cohorts will be opened: the first cohort will undergo surgical resection immediately after completion of anthracycline-based chemotherapy, and the second cohort will undergo taxane-based chemotherapy following completion of anthracycline-based chemotherapy.
Trial: NCT01634230
Drug: OCR-002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily dose: 10 g infused over 24 hours
Trial: NCT05160506
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone is a steroid (corticosteroid) medication.
Trial: NCT05160506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50ml of 0.9% NACL will serve as the placebo
Trial: NCT04951765
Drug: XZP-3287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
Trial: NCT04951765
Drug: XZP-3287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
Trial: NCT04951765
Drug: XZP-3287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
Trial: NCT04951765
Drug: XZP-3287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle1 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast
Trial: NCT04951765
Drug: XZP-3287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle1 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle2 Day 1: one dose of XZP-3287 before starting a low-fat breakfast Cycle3 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast
Trial: NCT04951765
Drug: XZP-3287
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle1 Day 1: one dose of XZP-3287 after finishing a low-fat breakfast Cycle2 Day 1: one dose of XZP-3287 after finishing a high-fat breakfast Cycle3 Day 1: one dose of XZP-3287 before starting a low-fat breakfast
Trial: NCT04847440
Drug: AB-729
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
Trial: NCT05267535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT03646058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills, sublingual, specifically made to mimick buprenorphine pills
Trial: NCT02526303
Drug: Nadroparin Calcium and Warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
Trial: NCT05071612
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration at bedtime
Trial: NCT06175780
Drug: KY-0118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KY-0118 is to be injected intravenously with a dose of 0.3μg/kg, 1μg/kg, 3μg/kg, 6μg/kg, 12μg/kg, 24μg/kg, 36μg/kg, 48μg/kg or 64μg/kg until disease progresses or unacceptable tolerability occurs;
Trial: NCT06175780
Drug: KY-0118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KY-0118 is to be injected intravenously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
Trial: NCT06175780
Drug: KY-0118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KY-0118 is to be injected subcutaneously with a dose of dose1\~dose5 weekly until disease progresses or unacceptable tolerability occurs;
Trial: NCT05042401
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo low dose
Trial: NCT05042401
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo high dose
Trial: NCT05411107
Drug: Placebo Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06498115
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this arm will receive norepinephrine as a bolus dose to treat maternal hypotension during cesarean section under spinal anesthesia. The dosage will be determined using the upper and lower sequential distribution method (UDM). The aim is to investigate the effective dose (ED50 and ED95) of norepinephrine in maintaining maternal blood pressure stability and optimizing maternal outcomes during the procedure.
Trial: NCT04873440
Drug: Chemo-immunotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same chemotherapy and/or anti-PD-1 therapy before thei patients' enrolment were allowed. Whether and which should be given depends on the treatment regimen before enrollment.
Trial: NCT04738175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluent solution
Trial: NCT06281977
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programed as dexmedetomidine on infusion pump.
Trial: NCT04684381
Drug: L-glutamine
RxNorm normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic study
Trial: NCT05844202
Drug: Alveavax-v1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BA.2/Omicron optimized plasmid DNA vaccine for the prevention of COVID-19
Trial: NCT05844202
Drug: Janssen Ad26.COV2.S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccine by Janssen / Johnson \& Johnson
Trial: NCT05180214
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: analgesia
Trial: NCT05210504
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal (0.9%) Saline
Trial: NCT06334874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starch placebo capsule
Trial: NCT06046066
Drug: NM6603
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NM6603 is an orally available investigational small molecule indicated for the treatment of solid malignancies including, but not limited to breast, liver, pancreatic, colorectal, cervical, melanoma and lung cancers.
Trial: NCT04892706
Drug: IDP-126 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel applied to face once daily in the evening.
Trial: NCT04892706
Drug: IDP-126 Vehicle Gel
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel applied to face once daily in the evening.
Trial: NCT04892706
Drug: Epiduo® Forte Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel applied to face once daily in the evening.
Trial: NCT05494268
Drug: Carbohydrate
RxNorm normalized name: CARBOHYDRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative Carbohydrate Loading Drink
Trial: NCT06423144
Drug: PD-1/PD-L1 inhibits and anti-angiogenic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agents were administrated based on the instructions recommended
Trial: NCT05698147
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: high-dose Methotrexate 3.5 g/m2 intravenous infusion d1, every 28 days for 6 cycles during combination induction treatment.
Trial: NCT05673824
Drug: Huaier Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment period: oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, failure of treatment, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.~If the treatment of hepatobiliary malignancies needs to be changed due to disease progression, whether to continue the medication or not should be determined by the researcher.
Trial: NCT06069180
Drug: Flu/Cy/ATG or Cy/ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
Trial: NCT05973370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Trial: NCT03903549
Drug: [18F]P17-059
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning
Trial: NCT06401499
Drug: etoricoxib 60mg
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigator will compare effects of etoricoxib alone and in combination with pregabalin on pain relief in chronic low back pain participants
Trial: NCT06167226
Drug: Personalized Ayurveda treatment protocol
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treating physician decided and advised personalized Ayurveda treatment protocol based on disease and patient's condition
Trial: NCT05282875
Drug: management of immunosuppressive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 groups :~* Discontinuation of immunosuppressive agents~* Reduction of immunosuppressive agents~* Maintenance of immunosuppressive agents
Trial: NCT04636567
Drug: Nerindocianine for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedure: routine minimally invasive abdominopelvic surgery.
Trial: NCT06151470
Drug: Alpha-Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Trial: NCT06151470
Drug: α-adrenergic receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Trial: NCT04891913
Drug: SY-007/ Placebo 15mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
Trial: NCT04891913
Drug: SY-007/ Placebo 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
Trial: NCT04891913
Drug: SY-007/ Placebo 60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
Trial: NCT04676893
Drug: D418 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1T
Trial: NCT04676893
Drug: CKD-388 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1T
Trial: NCT04915508
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive hormonal therapy
Trial: NCT06011317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered orally once daily
Trial: NCT04834908
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care for COVID 19 infection based on the current guidelines and institutional practice will be provided
Trial: NCT05735756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once a day for 12 weeks
Trial: NCT04518254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will be administered 4 capsules of Lactose 500 mg (placebo) per oral route
Trial: NCT06511947
Drug: 5 Methoxy N,N Dimethyltryptamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH001 administered via inhalation
Trial: NCT05128071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to placebo twice daily
Trial: NCT00240812
Drug: ibuprofen; pseudoephedrine HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05056558
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued standard of care (SOC) together with oral placebo tablet from day 1 to day 14
Trial: NCT05023525
Drug: HSK31858, tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose in single ascending dose: 5 mg
Trial: NCT05023525
Drug: Placebo, tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT03787628
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. Different amounts (numbers of softgel capsules) of placebo will be administered to match that of the active compound, daily in the morning and afternoon for each of 28 days.
Trial: NCT05543122
Drug: either of Atenolol, Bupropion, Brivaracetam, Escitalopram, Fluconazole, Lacosamide, Lamotrigine, Levetiracetam, Methotrexate or Ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a cohort study of pharmacokinetics of drugs in milk. Participants in the group are those breastfeeding women on the listed drugs at steady state, who are prescribed these drugs for clinical reasons outside this study framework.
Trial: NCT05985707
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.
Trial: NCT05259007
Drug: Amoxicillin-Clarithromycin-Lansoprazole
RxNorm normalized name: AMOXICILLIN/CLARITHROMYCIN/LANSOPRAZOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H pylori eradication treatment
Trial: NCT06237595
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment for fibromyalgia patients
Trial: NCT06133556
Drug: MCBC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: using MCBC as conditioning regimen, Mel 60mg/ m2 -9\~-8d, Cladribine 5 mg/m2 -9\~-5d, Bu3.2mg/kg -5\~-3d； Cy 30mg/kg -2\~-1 d
Trial: NCT06133556
Drug: Bu/Cy regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group, the standard conditioning regimen Busulfan/Cyclophosphamide
Trial: NCT05120739
Drug: 2% CHX cloths
FDA approved: no
EMA approved: no
PMDA approved: no
Description: skin preparation in 2% CHX cloths
Trial: NCT05144828
Drug: Patient-controlled analgesia (PCA)
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will have access to the standard PCA (patient-controlled analgesia) offered at Froedtert Hospital. This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral. All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.
Trial: NCT05011149
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmacotherapy, when indicated (ie, for severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness), will be provided in the form of ibuprofen as first line agent at a standard dosing of 10 mg/kg followed by 2 doses of 5mg/kg every 24 h. The route of administration may be intravenous or enteral, as determined by the treating team.~For treated infants, follow-up echocardiography will be conducted at the end of the 3-day course and second course of treatment will be initiated if they still fulfill study treatment criteria as mentioned above. If any treatment-eligible infant has a contraindication to ibuprofen, use of acetaminophen will be permitted as an alternative agent.
Trial: NCT06387069
Drug: HMPL-306 Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive HMPL-306 monotherapy: HMPL-306 PO at 250 mg QD (C1) + 150 mg QD (starting from C2), 28 days as a cycle.